China’s (NMPA) has announced enhanced regulatory measures following the formal revision of the Implementing Regulations of the Drug Administration Law. The updated rules were promulgated through a State Council decree signed by Chinese Premier and will officially take effect on May 15, 2026.

The revised regulation, comprising nine chapters and 89 articles, is designed to promote pharmaceutical innovation, strengthen oversight of online drug sales, tighten manufacturing controls, and reinforce full life-cycle drug supervision. It establishes a more robust legal framework to ensure high-level drug safety and high-quality industry development.

Key Regulatory Enhancements

Clinical Value-Oriented Drug Innovation

At the core of the reform is a strengthened drug research and registration system. The revised regulations emphasize a clinical value-driven approach to drug development, encouraging meaningful innovation and supporting the clinical application and use of new medicines.

Key innovation incentives include:

• Accelerated review pathways for drug marketing authorization
• Market exclusivity for eligible pediatric medicines
• Market exclusivity for rare disease treatments
• Data protection for drugs containing new chemical substances
• Regulatory support for pediatric preparation development in medical institutions

Clearer procedures are also introduced for drug re-registration and for switching between prescription and over-the-counter status.

Strengthened Clinical Trial and Manufacturing Oversight

The updated rules refine clinical trial management requirements to enhance quality, safety, and compliance throughout development.

In manufacturing, the regulations tighten control mechanisms and clarify management requirements for:

• Production and sale of traditional Chinese medicine decoction pieces
• Traditional Chinese medicine granules
• Good Manufacturing Practice enforcement measures

Enhanced Oversight of Online Drug Sales

Recognizing the rapid expansion of digital healthcare, the revised framework strengthens supervision of online drug distribution.

Key measures include:

• Clearer compliance obligations for third-party e-commerce platform operators
• Increased accountability for online sales channels
• Stronger monitoring mechanisms to ensure product authenticity and patient safety

This marks a significant regulatory evolution in China’s pharmaceutical e-commerce landscape.

Reinforced Drug Safety Supervision

The NMPA reinforces full life-cycle drug safety oversight through:

• Specified inspection measures
• Detailed quality sampling and testing procedures
• The right to apply for re-testing if inspection results are disputed
• Clear and stringent legal liabilities for violations
• Intensified enforcement in high-risk areas

These measures aim to strengthen compliance, transparency, and accountability across the pharmaceutical supply chain.

Expanding Regulatory Capacity and Policy Implementation

To ensure effective implementation, the NMPA will:

• Strengthen policy interpretation and regulatory training
• Enhance coordination across the drug life cycle
• Advance regulatory science
• Optimize regulatory systems and workforce capabilities
• Update supporting regulations and technical guidelines

Strategic Impact

The revised Implementing Regulations reflect China’s continued commitment to a people-centered health policy, high-impact and science-based regulation, encouragement of pharmaceutical innovation, strengthened lifecycle supervision, and sustainable high-quality industry development.

With a clear emphasis on innovation incentives, online sales governance, manufacturing compliance, and stronger enforcement mechanisms, the updated framework signals a significant modernization of China’s drug regulatory system.

For More information: China revises drug administration regulations to spur innovation, tighten oversight